Ensign Peak Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Ensign Peak Advisors's BMY Position: Q3 2026 in Review
Ensign Peak Advisors reduced its Bristol-Myers Squibb (BMY) stake by 9.9% in Q3 2026, selling an estimated $18M and leaving 2,581,321 shares worth $161M. The position accounts for 0.27% of the portfolio, ranked #70.
Ensign Peak Advisors first reported a position in BMY in Q4 2019 and has held it in 28 quarters since. The position peaked at $351M in Q2 2022. 2,555 funds tracked by Wall St. Rank hold BMY as of Q3 2026.
- Ensign Peak Advisors held 2,581,321 shares of Bristol-Myers Squibb worth $161M as of Q3 2026.
- Ensign Peak Advisors sold 284,342 Bristol-Myers Squibb shares in Q3 2026, an estimated $18M.
- Bristol-Myers Squibb made up 0.27% of Ensign Peak Advisors's portfolio in Q3 2026, its #70 holding.
- Ensign Peak Advisors first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 28 quarters since.
- Ensign Peak Advisors's Bristol-Myers Squibb position peaked at $351M in Q2 2022.
- 2,555 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.
Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.